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1. Introduction
1.1. Diagnostic ability of 201thallium SPECT and 99mtechnetium methoxyisobutylisonitrile
SPECT for patients with initial glioma
Single photon emission computed tomography (SPECT) is a valuable diagnostic modality
for the evaluation of brain tumor malignancy and activity. Thallium-201 (Tl) SPECT and
Technetium-99m methoxyisobutylisonitrile (Tc-MIBI) SPECT were clinically used to evalu‐
ate brain tumor malignancy and activity. In addition, both early and delayed images were
taken depending on the preference of each institute. The results of SPECT examinations al‐
ways include some false positive or false negative findings. The diagnostic value of brain tu‐
mor SPECT has been evaluated using sensitivities and specificities with arbitrary cut off
values [1-8]. These arbitrary cut off values depend on the measurement methods used by
each institute, as a result, studies using these arbitrary cut off values are not useful for eval‐
uating tumor malignancy at other institutes.
A receiver operating characteristic (ROC) analysis is useful for evaluating the diagnostic
ability of different examinations that include some errors [9, 10]. In order to investigate the
ability of each SPECT modality to evaluate tumor malignancy, each SPECT modality was di‐
rectly compared for the patients with an initial glioma using an ROC analysis. The hypothe‐
sis is that the one SPECT modality is superior to any other modalities for grading glioma.
1.2. Methods
The study population included 59 patients  with glioma who were admitted to Tsukuba
University  hospital  between 1999  and 2005  and who underwent  SPECT imaging.  None
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of  the  patients  had received any  previous  radiation  therapy to  the  brain  and recurrent
cases  were  excluded.  Tl  and  Tc-MIBI  SPECT  images  were  taken  before  surgery,  radia‐
tion or chemotherapy in most patients.  The SPECT images were taken after surgery but
before  radiation  or  chemotherapy  in  one  patient.  All  pathological  diagnoses  were  con‐
firmed  after  the  surgical  removal  of  the  tumor.  The  benign  group  included  low  grade
astrocytomas (n=23) and a central neurocytoma (n=1) while the malignant group includ‐
ed anaplastic  astrocytomas (n=10)  and glioblastomas (n=25).  The benign group included
13 men and 11 women,  ranging from 3 to 59 years  of  age and the median age was 32
years  old.  The malignant  group included 17 men and 18 women,  ranging from 7 to  79
years of age and the median age was 55 years old.
Tl SPECT and Tc-MIBI SPECT images were obtained 15 min (early) and 3 hr (delayed) after
the intravenous injection of 74 MBq of Tl chloride or 740 MBq of Tc-MIBI using a multi-detector
SPECT machine (E.CAM, Siemens Medical, Malvern, PA) and a high resolution collimator
(LEHR, Siemens Medical, Malvern, PA). The Butterworth pre-correction filter and the Chang
method were used for pre and post attenuation corrections. The Ramp filter was used for
reconstruction. The image matrixes for Tl and MIBI SPECT were 64x64 and 128x128. The pixel
sizes for Tl and MIBI SPECT were 6.61mm and 3.31mm. The slice thickness both of Tl and MIBI
SPECT was 6.61mm.
The Regions of Interest (ROI) were set on tumor and contra-lateral normal white matter
in reconstructed SPECT images.  The ROIs were customized for each patient.  In the cas‐
es  with  a  hot  tracer  uptake  into  the  tumor,  the  ROIs  were  placed  at  homogeneously
high  uptake  areas.  In  cases  with  no  tracer  uptake,  the  ROIs  were  placed  at  suspected
tumor areas using the MRI findings as references.  All  ROIs were selected by independ‐
ent  radiology technologists.  Tumor/Normal  (T/N)  ratios  were calculated as  the  ratios  of
radioactivity in the ROIs.  The diagnostic abilities of the T/N ratios for malignancy were
analyzed  by  an  ROC  analysis  using  the  ROCKIT1.1B2  Beta  and  PlotROC.xls  software
programs  (University  of  Chicago).  The  area  z-score  (Az)  values  were  calculated  from
the  areas  under  the  ROC  curves  and  the  diagnostic  accuracy  was  compared  between
each  imaging  modality.  Any  differences  in  the  Az  values  were  analyzed  using  the  bi‐
variate x2 test.
1.3. Results
Figure 1 shows the ROC curves. The vertical axis is the true positive fraction (TPF) that
means sensitivity and the horizontal axis is the false positive fraction (FPF) that is same
value  of  1-specificity.  The  ROC curve  of  the  early  MIBI  shifted  to  upper  right  and the
sensitivity  was  better  than the  other  in  the  high FPF area,  however  the  sensitivity  was
low in the low FPF area.  The ROC curve of  the delayed MIBI shifted to the upper left
and showed well  balanced high sensitivity and specificity.  The ROC curves of the early
and  delayed  Tl  were  almost  same  and  showed  lower  sensitivity  and  specificity  than
that of the delayed MIBI in most areas.
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neurocytoma showed high Tl uptake and no MIBI uptake (Figure 1). In this case, MIBI SPECT was more accurate than Tl SPECT to 
evaluate tumor malignancy, because central neurocytoma is a benign tumor. Pilocytic astrocytoma is one of the most benign 
gliomas and the Tl SPECT findings of a pilocytic astrocytoma are reported to show a variable uptake [8]. 
1.4.2. Tc-MIBI SPECT 
Tc-MIBI SPECT is reported to be useful to diagnose brain tumor recurrence [22, 23], high S-phase fraction and aneuploidy [24], 
tumor volume and survival [25, 26], and, differential diagnosis of radiation necrosis [27]. The Tc-MIBI index, the ratio of 
radioactivity of the ROI at the lesion and normal brain, was used to differentiate low and high grade gliomas [28], recurrence and 
radiation necrosis [22] and the estimation of the prognosis [25, 26]. However there are some false positive and false negative cases 
reported [23]. Tc-MIBI is concentrated in the mitochondria as the result of active diffusion due to increased metabolic needs [22]. 
Tc-MIBI uptake is determined by tumor malignancy, viability, density, oxygenation, vascular supply, and blood brain barrier (BBB) 
disruption [29]. These factors are not linearly correlated, because glioblastoma, the most malignant form of glioma, is 
pathologically heterogeneous including internal necrosis. False negative MIBI SPECT may occur due to the lack of contrast uptake 
on MRI and masked by other normal tissue uptake. This was seen in temporal and periventricular tumors [23], because Tc-MIBI is 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
FPF 0.095 0.195 0.295 0.395 0.495 0.595 0.695 0.795 0.895 0.995
Delayed MIBI a=1.96
b=0.88 Az=0.9294
Early a=2.34 b=1.49
Az=0.9039
Delayed Tl a=1.85 b=0.99
Az=0.9057
Early MIBI a=4.30 b=3.71
Az=0.8684
sensitivity 
specificity 
Figure 1. Receiver operating characteristic (ROC) curves
1.4. Discussion
1.4.1. Tl SPECT
Tl SPEC  is useful for identifying the presence of a tumor [1 ], t or malignancy [1, 6, 12]
and for mak ng a differential diagnosis t  distinguish tumor recurrence from radiation necr sis
[6, 12, 13]. The Tl i dex, the ratio of radioactivity of ROI at the lesion and normal brain, was
used to differentiate low and high grade glioma [1], recurrence and radiation necrosis [2, 3].
The dynamic Tl SPECT is reported to be useful to evaluate tumor vascularity, histology and
malignancy [14, 15]. However there are some false positive and false negative cases reported
[6, 7, 12, 16, 17]. Inflammation after surgery or radiation is a major cause of false positive Tl
uptake. The causes of false negative findings may include small tumor size, histological
heterogeneity, cystic or necrotic com onents, or a low threshold of the detector or imaging [18,
19]. Both of central neurocytoma and ganglioglioma are benign glioma. High Tl uptake in a
central neurocytoma and ganglioglioma were reported [20] [21]. High cell density and high
metabolic rate are thought to explain the high Tl uptake in these low proliferative tumors. In
the present series, one patient with a central neurocytoma showed high Tl uptake and no MIBI
uptake. In this case, MIBI SPECT was more accurate than Tl SPECT to evaluate tumor
malignan y, because central n urocytoma is a benign tumor. Pilocyti  astrocytoma is one of
Recent Developments of Single Photon Emission Computed Tomography for the Diagnosis of Brain Tumors
http://dx.doi.org/10.5772/52352
109
the most benign gliomas and the Tl SPECT findings of a pilocytic astrocytoma are reported to
show a variable uptake [8].
1.4.2. Tc-MIBI SPECT
Tc-MIBI SPECT is reported to be useful to diagnose brain tumor recurrence [22, 23], high S-
phase fraction and aneuploidy [24], tumor volume and survival [25, 26], and, differential
diagnosis of radiation necrosis [27]. The Tc-MIBI index, the ratio of radioactivity of the ROI at
the lesion and normal brain, was used to differentiate low and high grade gliomas [28],
recurrence and radiation necrosis [22] and the estimation of the prognosis [25, 26]. However
there are some false positive and false negative cases reported [23]. Tc-MIBI is concentrated in
the mitochondria as the result of active diffusion due to increased metabolic needs [22]. Tc-
MIBI uptake is determined by tumor malignancy, viability, density, oxygenation, vascular
supply, and blood brain barrier (BBB) disruption [29]. These factors are not linearly correlated,
because glioblastoma, the most malignant form of glioma, is pathologically heterogeneous
including internal necrosis. False negative MIBI SPECT may occur due to the lack of contrast
uptake on MRI and masked by other normal tissue uptake. This was seen in temporal and
periventricular tumors [23], because Tc-MIBI is physiologically taken into the orbita, naso‐
pharyngeal tissues, pituitary, scalp and choroid plexus [30]. Some of the false positive results
were due to recent radiation induced local disruption of the BBB [23].
The pixel  size  of  MIBI  SPECT was smaller  than that  of  Tl  SPECT in  this  study.  There‐
fore,  MIBI  SPECT has a  higher  spatial  resolution than Tl  SPECT.  This  study investigat‐
ed  the  diagnostic  ability  of  SPECT  for  glioma  malignancy.  Higher  spatial  resolution
might influence the diagnostic ability with small or heterogeneous tumors. However, all
of  the  gliomas  in  this  study  were  larger  than  the  pixel  size.  In  addition,  most  of  the
malignant  tumors in  this  study were highly heterogeneous in both of  MRI and SPECT.
Only the  higher  spatial  resolution of  MIBI  SPECT could not  explain the  slightly  higher
diagnostic  ability  of  MIBI  SPECT  than  that  of  Tl  SPECT.  Some  authors  have  reported
that  Tc-MIBI  SPECT  has  higher  sensitivity  and  specificity  than  that  of  Tl  SPECT  for
adult and childhood brain tumors and differential  diagnosis of recurrence and radiation
necrosis  [26,  27,  31].  However,  other  authors  did  not  [32].  This  discrepancy  may  be
caused  by  small  and  heterogeneous  patient  populations  and  arbitrary  selected  cut  off
values.  In  Tl  SPECT there  is  some normal  brain  uptake,  this  makes  T/N ratio  low.  Tc-
MIBI  has  high  photon  energy  level  and  higher  tumor/background  ratio  in  comparison
with Tl  SPECT and yields clear  SPECT images and high sensitivity for  malignant  brain
tumor [22, 27, 31].
P-glycoprotein is one of the drug efflux pumps in the cell membrane and it acts to remove Tc-
MIBI from tumor cells [33, 34]. Other studies have suggested that p-glycoprotein expression
in malignant glioma is the cause of false negative with Tc-MIBI SPECT [35-37]. The effect of p-
glycoprotein expression on clinical Tc-MIBI SPECT images has been investigated, and this
effect was negligible in the diagnosis of brain tumor malignancy [38]. Henze also reported that
p-glycoprotein efflux does not contribute to false negative MIBI SPECT, since MIBI washout
did not occur between the early and late SPECT scans [39].
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1.4.3. ROC analysis
Many facilities use a cut off value to evaluate tumor malignancy in Tl or Tc-MIBI SPECT [1,
4-8]. Serizawa reported that simple inter-institutional comparisons of Tl indices are not
possible because measurement methods are different in each institute [7].
Most diagnostic tests have some errors and the results are influenced by arbitrary selected cut
off values. ROC analysis is useful to evaluate the diagnostic values of each examination that
yield some false positive or false negative results [9, 10]. Henze reported that ROC analysis
comparing I-123-iodo-α-methyl-L-tyrosine (IMT), Tc-MIBI SPECT and F-18-fluorodeoxyglu‐
cose positron emission computed tomography (FDG PET) for detection of tumor progression
in irradiated low-grade astrocytoma demonstrated that IMT yielded best diagnostic accuracy
[29]. ROC analysis has better diagnostic power than the arbitrary cut off method and inde‐
pendent disease prevalence and decision-making threshold [29]. ROC analysis also provides
adequate cut off value with appropriate sensitivity and specificity. Because SPECT image
accuracy is dependent on SPECT machine quality, acquisition algorithm, and injected isotope
dose, each facility should determine its own cut off value to provide an adequate diagnosis
from an ROC analysis of own data.
Some facilities omitted the acquisition of delayed images due to their limited examination time.
However, the current results demonstrated the superior diagnostic value of delayed images
in both of Tl and Tc-MIBI SPECT. These results revealed both Tl and Tc-MIBI SPECT are useful
for the diagnosis of gliomas. However, the SPECT study is not perfect, there are still some false
positive and false negative findings. Multi-modality imaging studies may therefore help to
diagnose brain tumors more correctly. If it is necessary to limit SPECT examinations due to
medical economical issues related to the health insurance policy, then Tc-MIBI SPECT with a
delayed acquisition is therefore considered to be the most reasonable choice.
1.5. Conclusion
Both of Tl and Tc-MIBI SPECT are useful imaging modalities for the evaluation of glioma
malignancies. Although there was no statistically significant difference, delayed Tc-MIBI
SPECT demonstrated the best diagnostic value in our patients with glioma based on an ROC
analysis.
2. Coregistration of functional SPECT images and high resolution
anatomical MRI
2.1. Introduction
201Thallium Single Photon Emission Computed Tomography (Tl SPECT) is a useful functional
imaging modality for the diagnosis of malignancy and activity of brain tumors. One of the
drawbacks of Tl SPECT is its low spatial resolution. The coregistration of functional SPECT
images and high resolution anatomical magnetic resonance imaging (MRI) is considered to be
a reasonable method to improve the low spatial resolution of SPECT.
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Some methods developed for the coregistration of multiple images have been reported. One
is a prospective method using external markers[40-42]. Another is the retrospective methods
based on imaging data[43-46]. Prospective methods need prospective external fiducial marker
placement and only the image with the marker can be coregistered. Retrospective methods do
not need external markers, and therefore they are more flexible. Variable images can be
retrospectively coregistered using software programs.
A newly developed software Brain Easy Analysis Tool for 201Tl-SPECT (BEAT-Tl, Fuji Film
RI Pharma. Tokyo, Japan) was used for the coregistration of Tl SPECT and MRI in patients
with brain tumors. The feasibility and reliability of BEAT-Tl was evaluated for patients with
brain tumors.
2.2. Materials and methods
The patient population included 98 patients (47 men and 51 women). The age range was from
4 to 84 years of age and the median age was 54. All patients had been admitted to Tsukuba
University Hospital between 2004 and 2007. The brain MRI and Tl SPECT images were taken
within a 1 week interval. No anti-tumor therapy was administered between the examinations.
The sets of MRI and Tl SPECT examinations were taken for 120 times (59 times for men and
61 times for women). MRI showed mass lesions in all of the patients. The final diagnoses
included glioma, lymphoma, neurocytoma, metastasis, meningioma, radiation necrosis,
encephalitis and multiple sclerosis. Most patients underwent tumor removal surgery and the
pathological diagnoses were determined.
MRI was performed using the 1.5  Tesla  clinical  MRI scanner (Gyroscan NT Intera,  Phi‐
lips,  Netherlands).  T1  weighted  images  with  or  without  Gd-DTPA  enhancement,  T2
weighted images and Fluid attenuated inversion recovery images (FLAIR) were routine‐
ly acquired. Tl SPECT images were acquired 15 minutes (early image) and 3 hours (de‐
layed image)  after  the  intravenous injection of  74  MBq of  Thallium Chloride (Fuji  Film
RI  Pharma.  Tokyo,  Japan)  using  a  multi-detector  SPECT  machine  (E.CAM,  Siemens
Medical,  Erlangen, Germany) and a high resolution collimator (LEHR, Siemens Medical,
Erlangen,  Germany).  The  Butterworth  pre-correction  filter  and the  Chang method were
used for pre and post attenuation corrections.  The Ramp filter was used for reconstruc‐
tion.  The image matrixes  for  Tl  SPECT were 64 x  64.  Both the pixel  sizes  and the slice
thickness for Tl SPECT were 6.61mm.
The MRI and SPECT data were saved as Digital Imaging and Communications in Medi‐
cine  (DICOM)  formats.  The  DICOM  data  were  converted  to  the  analyze  format  using
File  Converter  Ver.  2.5  (Fuji  Film RI  Pharma.  Tokyo,  Japan).  Both  the  MRI  and SPECT
data  in  analyze  format  were  transferred to  the  co-registration  software  program BEAT-
Tl and then coregistered images were created. The BEAT-Tl program is based on Statis‐
tical  Parametric  Mapping  (SPM)  and  it  can  be  used  on  personal  computers  with  the
Windows operating system. The imaging quality,  clinical  usefulness  and the artifacts  of
the coregistered images were evaluated by visual inspection.
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2.3. Results
The coregistered images were easily and promptly created within one minute. The image
quality was sufficient. There were no large displacements of the MRI and SPECT images and
no major artifacts. The coregistration was fully automatic and no manual coregistration
procedure was required.
The small hot uptake in Tl SPECT always coincided with enhanced tumors in MRI. For large
tumors, Gd enhanced T1 weighted MRI showed relatively homogeneous enhancement.
However, Tl SPECT showed focal uptake of Tl in the homogeneously enhanced tumor.
Therefore, the coregistered images demonstrated metabolic heterogeneity on Tl SPECT. In
most patients, Tl hot uptake was in the Gd enhanced tumor. In some patients, Tl uptake was
observed outside of the Gd enhanced tumor.
2.4. Illustrative cases
Case 1:A 64-year-old female with an anaplastic oligodendroglioma
Tl uptakes were different between 2 fusion images of Gd enhanced T1 weighted MRI and early
Tl SPECT (Fig. 2, Lt) or delayed Tl SPECT (Fig.2,Rt). Tl uptakes were heterogeneous even
though the Gd enhanced tumor was homogenous. Most Tl uptakes were within the Gd
enhanced tumor. However the part of the delayed Tl uptake was out of the Gd enhanced area,
and therefore this region seemed to demonstrate tumor invasion into normal brain tissue.
Figure 2. Fusion images of Gd enhanced T1 weighted MRI and early Tl SPECT (Lt) or delayed Tl SPECT (Rt) of Case 1.
Recent Developments of Single Photon Emission Computed Tomography for the Diagnosis of Brain Tumors
http://dx.doi.org/10.5772/52352
113
Case 2: A 34-year-old male with a frontal glioblastoma.
A fusion image of the preoperative Gd enhanced MRI and delayed Tl SPECT (Fig 3, Lt) showed
Rt medial Tl uptake although the Gd enhanced tumor was located in the corpus callosum.
Because there was a tumor without Gd enhancement in the left frontal lobe, the left frontal
lobe and the tumor at the corpus callosum was removed. After radiation therapy of 60Gy, 2
months after the surgery, tumor recurrence was seen mainly in the Rt medial frontal lobe where
the hot Tl uptake was seen in Gd enhanced T1 weighted MRI (Fig 3, Rt).
Figure 3. Fusion image of preoperative Gd enhanced MRI and delayed Tl SPECT (Lt) and Gd enhanced T1 weighted
MRI (Rt) 2 months after the surgery.
2.5. Discussion
2.5.1. Usefulness of coregistration
The one of the major disadvantages of SPECT is the low spatial resolution caused by scattering
radiation. Because no anatomical landmarks are seen in Tl SPECT images, it is sometimes
difficult to precisely determine the locations of lesions and the relationships with normal
structures based on only Tl SPECT images. The coregistration of Tl SPECT and MRI has thus
completely solved these problems.
Even when tumors were found to be homogeneous in MRI, Tl SPECT showed metabolic
heterogeneity. These detailed analyses thus become possible by studying coregistration
images. Further pathological and clinical studies are expected to reveal the clinical significance
of these imaging modalities.
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2.5.2. Method of coregistration
Other methods for the coregistration of SPECT and MRI has been reported [45-47]. These
methods required meticulous and cumbersome procedures and long calculation time. In some
cases sufficient coregistration could not be achieved by automatic calculations and thus
required manual procedures.
The Brain easy analysis tool (BEAT, Fuji film RI Pharma, Tokyo, Japan) is the coregistration
program for cerebral blood flow (CBF) SPECT and MRI. BEAT uses automated image regis‐
tration (AIR http://bishopw.loni.ucla.edu/) as the coregistration algorithm and ratio image
uniformity (RIU) as the cost function. In CBF SPECT image, tracer uptake into normal brain
tissue is seen, so the contour of the brain tissue is clear. However, in the brain tumor SPECT
image, the tracer uptake into the normal brain tissue is negligible, so the contour of the normal
brain tissue is not seen. Because of these factors, the coregistration of brain tumor SPECT and
MRI has not been achieved using the same algorithm used for the coregistration of CBF SPECT
image and MRI.
BEAT-Tl uses statistical parametric mapping (SPM) 2 (http://www.fil.ion.ucl.ac.uk/spm/) as
the voxel based coregistration software and normalized mutual information (NMI) as the cost
function to evaluate coregistration accuracy. These algorithms allow automatic coregistration
of brain tumor SPECT and MRI with satisfactory accuracy.
The BEAT-Tl program runs on a normal personal computer without any problems. The usual
calculation time is within a minute, so it is simple for operators. The results could be fed back
to a busy daily clinical practice, so the clinical impact and efficacy are significant. In the current
study, the accuracy of the coregistration was satisfactory. There were no major errors or
artifacts.
SPECT/computed tomography (CT) or positron emission CT (PET)/CT are thus considered to
be alternative methods to create coregistration images. These hardware based coregistrations
must be more accurate than the software based coregistrations. Currently, however, these
machines are expensive and not available in most clinical settings. As the results, the coregis‐
tration software program is both a convenient and sufficiently accurate method to create
coregistration images in most clinical facilities.
2.5.3. Study limitation
The current study population was relatively small and this study did not evaluate every patient
admitted to this hospital. In the future, a prospective study will reveal the exact usefulness
and the limitations of the coregistration images of Tl SPECT and MRI.
The uptake of Tl into a lesion is affected by multiple factors, including tumor malignan‐
cy,  tumor  metabolism,  cell  density,  blood  brain  barrier  breakdown,  blood  flow,  blood
volume and capillary density [1,  5].  Therefore, the interpretation of Tl SPECT should be
done  cautiously.  The  fusion  of  Tl  SPECT  and  MRI  could  be  helpful  to  evaluate  the
mechanisms  of  Tl  uptake  into  lesions.  Although no  large  displacements  of  the  coregis‐
tration  were  seen  in  the  images  created  by  BEAT-Tl,  the  coregistration  error  was  not
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measured  in  this  study.  In  order  to  investigate  the  coregistration  error,  stereotactic  or
image  guided  surgery  will  be  done  in  a  future  study.  One  of  the  problems  of  image
study  for  malignant  brain  tumors  is  the  heterogeneity.  Glioblastoma  multiforme  is
pathologically,  metabolically,  and radiologically  heterogeneous.  Pathological  radiological
correlations could reveal the meaning of each finding. Neurosurgeons could remove the
tumor; however,  the registration of the removed tissue at exact locations on each image
is  not  easy.  Image  guided  surgery  using  coregistration  image  should  facilitate  these
studies.  The  application  of  fusion  images  for  navigation  guided  neurosurgery  will  be
developed.
2.6. Conclusion
BEAT-Tl is a useful coregistration software program that is used to evaluate brain tumors. It
improves the spatial correlation of SPECT images and such coregistration images demonstrate
a metabolic heterogeneity in tumors that is not revealed in MRI.
3. Evaluation of glioma surgical extent using fusion image of Tl SPECT and
anatomical MRI
3.1. Introduction
In glioma surgery, removal extent has been evaluated using morphological image, such as MRI
or X-ray CT. These morphological images could not completely evaluated surgical removal
extent, because glioma is invasive tumor. The contribution of glioma surgery for the improve‐
ment of the prognosis is controversial [48, 49]. One of the causes of this discrepancy may be
the method of evaluation of glioma surgical extent. We evaluated the glioma surgical extent
using fusion image of metabolic Tl SPECT and anatomical MRI. Our hypothesis is these fusion
images could more precisely predict the prognosis of the patient received glioma removal
surgery.
3.2. Methods
From 2006 to 2008, 146 patients examined both of Tl SPECT and MRI at the same time under
the diagnosis of brain tumor. And 58 patients received tumor removal surgery after the
examinations. Only 36 patients who were examined MRI within 3 days after the surgery were
included because surgical modification of MRI increase after postoperative 4 days [50]. Finally
30 patients who have Gd-DTPA enhanced tumor in MRI and hot tumor uptake in Tl SPECT
were included in this study, in order to make image evaluation easy. Final patient population
included 17 male and 13 female, age range from 34 to 80 year-old. World Health Organization
(WHO) pathological grade are 10 grade 3 and 20 grade 4. Oligodendroglioma component was
recognized in 7 grade 3 tumors. All patients received adjuvant standard radiation and
chemotherapy.
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3.3. Results
Partial removal group were frequently seen in Grade 4. The removal rates with MRI and SPECT
were concordant for 24 cases. The removal rates with MRI were higher than those with SPECT
in 6 cases. So SPECT more efficiently revealed residual tumor than MRI did (Figure 4,5). The
time to progression was short in partial removal group with MRI and SPECT (Figure 6). The
removal rates, pathology and oligodendroglioma components were all related with the
prognosis in multivariate analysis.
 
(a) 
(b) 
(e) (c) 
(d) 
(a): preoperative Gd-enhanced MRI showed left frontal non-enhanced low intensity tumor and Gd-enhanced tumor.
Enhanced tumor located at left medial frontal lobe and invaded into right medial frontal lobe.
(b): The fusion image of preoperative Tl-SPECT and MRI showed hot Tl uptake only at right medial frontal lobe.
(c): Postoperative Gd-enhanced MRI showed small residual enhanced tumor at right medial frontal lobe.
(d): The fusion image with Tl-SPECT demonstrated residual tumor at right medial frontal lobe. Surgical extents were
evaluated as subtotal removal by MRI, partial removal with Tl-SPECT.
(e): After radiation and chemotherapy, tumor recurrence occurred from right medial frontal residual tumor.
(Reproduced from Y Shibata, CI research 32:19-24, 2010 with permission.)
Figure 4. Case 1, 34 year-old man with glioblastoma. (same case as Fig 2-2)
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 (a) 
(b) 
(e) (c) 
(d) 
(a): Preoperative Gd-enhanced MRI showed right parietal ring enhanced tumor and perifocal edema.
(b): The fusion image of preoperative Gd-enhanced MRI and Tl SPECT
(c): Postoperative Gd-enhanced MRI showed small residual enhanced tumor at right parietal lobe.
(d): The fusion image of preoperative Tl SPECT and MRI showed hot Tl uptake at right residual parietal lobe.
(e): After radiation and chemotherapy, tumor recurrence occurred from hot Tl uptake area.
(Reproduced from Y Shibata, CI research 32:19-24, 2010 with permission.)
Figure 5. Case 2, 57 year-old woman with glioblastoma.  
Book Title 16
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Fig. 3‐3: Kaplan‐Meier curves of Time to Progression evaluated by removal rate in 2 
MRI  (Left)  and  SPECT  (Right).  Partial  removal  groups  (brown  curves)  showed 3 
significantly  early  recurrences  than  both  of  total  (blue  curves)  and  sub‐total 4 
removal groups (blue curves). 5 
3.4.   Conclusion 6 
The  fusion  image of preoperative  Tl  SPECT  and postoperative MRI  is more 7 
useful to evaluate glioma removal extent than MRI only. Partial removal groups 8 
have  poor  prognosis,  so  maximum  surgical  removal  should  be  aimed  using 9 
multimodal  images  including MRI and Tl SPECT. The total removal of Tl SPECT 10 
positive lesion improves the prognosis and especially prevents early recurrence. 11 
4. Conflict of interest 12 
 I declare that I have no conflict of interest. 13 
5. Acknowledgements 14 
 I appreciate my mentors, collaborators and the patients.  15 
 16 
6. References 17 
[1] Black  KL,  Hawkins  RA,  Kim  KT,  Becker  DP,  Lerner  C,  Marciano  D.  Use  of 18 
thallium‐201 SPECT  to quantitate malignancy grade of gliomas.  J Neurosurg. 19 
1989;71:342‐6. 20 
[2] Kosuda  S,  Shioyama  Y,  Kamata  N,  Suzuki  K,  Tanaka  Y,  Nakamura  O,  et  al. 21 
[Differential  diagnosis  between  recurrence  of  brain  tumor  and  radiation 22 
TTP
302520151050
1.0
0.8
0.6
0.4
0.2
0.0
TTP
302520151050
1.0
0.8
0.6
0.4
0.2
0.0
Figure 6. Kaplan-Meier curves of Time to Progression evaluated by rem val rate in MRI (Left) and SPECT (Right). Partial
removal groups (brown curves) showed significantly early recurrences than both of total (blue curves) and sub-total
removal groups (blue curves).
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3.4. Conclusion
The fusion image of preoperative Tl SPECT and postoperative MRI is more useful to evaluate
glioma removal extent than MRI only. Partial removal groups have poor prognosis, so
maximum surgical removal should be aimed using multimodal images including MRI and Tl
SPECT. The total removal of Tl SPECT positive lesion improves the prognosis and especially
prevents early recurrence.
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